TA-1 · Thymalfasin · Zadaxin® · 28 Amino Acid Thymic Peptide
A naturally occurring thymic peptide and the most clinically validated immune modulator in the peptide space. Approved as a pharmaceutical drug (Zadaxin) in 37 countries for hepatitis B, hepatitis C and immune restoration. Extensively studied for T-cell function, viral suppression and immune reconstitution in immunocompromised patients.
Thymosin Alpha-1 (TA-1) is a 28 amino acid peptide naturally produced by the thymus gland. It was first isolated in 1977 by Dr. Allan Goldstein at George Washington University as the active component of thymosin fraction 5 — a thymic extract that had demonstrated immune-modulating properties. It is commercially available as Zadaxin (thymalfasin) and has been approved in 37 countries as a pharmaceutical treatment for chronic hepatitis B, chronic hepatitis C and as an immune adjuvant in cancer treatment.
TA-1 has more completed human clinical trial data than virtually any other peptide in the research community — making it one of the most evidence-backed compounds available.
TA-1 is a biological response modifier that works through multiple immune pathways simultaneously:
The strongest human evidence for TA-1 comes from hepatitis research. Multiple Phase II and III trials demonstrated that TA-1 at 1.6mg twice weekly produced significantly higher rates of viral clearance in chronic hepatitis B and C compared to standard treatment alone. These results led to pharmaceutical approval in 37 countries.
In HIV/AIDS research, TA-1 demonstrated significant restoration of CD4+ T-cell counts and reduction in opportunistic infections including herpes virus reactivation — directly relevant to its application in herpes suppression protocols.
TA-1's mechanism is particularly relevant to herpes simplex virus (HSV-1 and HSV-2) and varicella-zoster virus (VZV, which causes shingles) suppression. Both viruses establish latency in nerve ganglia and reactivate when CD8+ T-cell immune surveillance declines — exactly the cellular pathway that TA-1 restores.
Clinical studies in immunocompromised patients have demonstrated that TA-1 supplementation significantly reduces herpes reactivation frequency by restoring the CD8+ cytotoxic T-cell surveillance that keeps latent virus dormant. This makes it particularly relevant for individuals on growth hormone-stimulating protocols (CJC-1295/Ipamorelin, HGH) where elevated IGF-1 can suppress T-cell function and trigger herpes reactivation.
The combination of TA-1 with standard antiviral approaches (L-Lysine, zinc, quercetin) addresses both viral replication suppression and immune surveillance restoration — a more comprehensive approach than either intervention alone.
Major surgery, including cardiac procedures, produces significant and prolonged immune suppression. Type 2 diabetes is independently associated with impaired T-cell function and reduced immune surveillance. Age-related thymic involution further reduces T-cell output from the fourth decade of life onwards. TA-1 addresses all three of these factors simultaneously — making it particularly relevant for older post-surgical diabetic patients.
Research in post-surgical patients has demonstrated that TA-1 significantly reduces infection rates and accelerates immune reconstitution compared to standard care. The compound's clean safety profile and lack of interactions with cardiovascular medications makes it suitable for post-cardiac surgery patients.
Across all completed clinical trials involving thousands of patients, TA-1 has demonstrated an excellent safety profile. The most commonly reported effects are mild injection site reactions. No serious adverse events have been attributed to TA-1 in published literature. It has no known interactions with common cardiovascular medications, diabetes medications or statins.
As an immune activator, TA-1 is theoretically contraindicated in active autoimmune conditions where immune stimulation could worsen the underlying disease — individuals with autoimmune conditions should discuss this with their physician before use.
Shingles reactivation is a reliable biomarker of impaired T-cell immune surveillance — the same mechanism TA-1 directly addresses. A history of recurrent shingles episodes indicates that VZV-specific CD8+ T-cell surveillance is insufficient to maintain viral latency. TA-1's restoration of CD8+ T-cell function provides a mechanistically appropriate intervention for reducing shingles reactivation frequency alongside standard antiviral management.